Skip to main content
Erschienen in: Reviews in Endocrine and Metabolic Disorders 2/2020

01.06.2020

Aggressive pituitary tumors in the young and elderly

verfasst von: Christina Tatsi, Constantine A. Stratakis

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Aggressive pituitary tumors (APTs) represent rare pituitary adenomas (PAs) with local invasion of surrounding tissues, increased risk for multiple recurrence, rapid tumor growth, or resistance to standard therapies. The most common APTs in children and adolescents are giant prolactinomas and somatotropinomas. Few cases of Crooke’s cell adenomas, silent corticotroph adenomas and pituitary carcinomas have also been reported in the literature. Pediatric patients with APTs have higher risk of harboring germline genetic defects, most commonly in the MEN1 and AIP genes. Since certain genetic defects confer a more aggressive behavior to PAs, genetic testing should be considered in tumors with young onset and positive family history. The management of pediatric APTs involves usually a combination of standard therapies (surgical, medical, radiation). Newer agents, such as temozolomide, have been used in few cases of pediatric pituitary tumors with promising results. In the elderly, PAs are more commonly non-functioning. Their management often poses dilemmas given the coexistence of age-related comorbidities. However, standard surgical treatment and temozolomide seem to be safe and well tolerated in elderly patients.
Literatur
7.
Zurück zum Zitat WHO. Classifcation of tumours of endocrine organs. (IARC Publications, Lyon, 2017). WHO. Classifcation of tumours of endocrine organs. (IARC Publications, Lyon, 2017).
9.
Zurück zum Zitat Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1–G24. https://doi.org/10.1530/EJE-17-0796.CrossRef Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178:G1–G24. https://​doi.​org/​10.​1530/​EJE-17-0796.CrossRef
10.
Zurück zum Zitat Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126:123–35. https://doi.org/10.1007/s00401-013-1084-y.CrossRef Trouillas J, Roy P, Sturm N, Dantony E, Cortet-Rudelli C, Viennet G, et al. A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol. 2013;126:123–35. https://​doi.​org/​10.​1007/​s00401-013-1084-y.CrossRef
11.
Zurück zum Zitat McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178:265–76. https://doi.org/10.1530/EJE-17-0933.CrossRef McCormack A, Dekkers OM, Petersenn S, Popovic V, Trouillas J, Raverot G, et al. Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. Eur J Endocrinol. 2018;178:265–76. https://​doi.​org/​10.​1530/​EJE-17-0933.CrossRef
16.
17.
Zurück zum Zitat de Castro LF, Magalhães Gonzaga MF, Naves LA, Luiz Mendonça J, Oton de Lima B, Casulari LA. Beneficial effects of high doses of Cabergoline in the treatment of Giant Prolactinoma resistant to dopamine agonists: a case report with a 21-year follow-up. Horm Res Paediatr. 2018;89:63–70. https://doi.org/10.1159/000479511.CrossRefPubMed de Castro LF, Magalhães Gonzaga MF, Naves LA, Luiz Mendonça J, Oton de Lima B, Casulari LA. Beneficial effects of high doses of Cabergoline in the treatment of Giant Prolactinoma resistant to dopamine agonists: a case report with a 21-year follow-up. Horm Res Paediatr. 2018;89:63–70. https://​doi.​org/​10.​1159/​000479511.CrossRefPubMed
22.
Zurück zum Zitat Cook RJ, Uttley D, Wilkins PR, Archer DJ, Bell BA. Prolactinomas in men masquerading as invasive skull base tumours. Br J Neurosurg. 1994;8:51–5.CrossRef Cook RJ, Uttley D, Wilkins PR, Archer DJ, Bell BA. Prolactinomas in men masquerading as invasive skull base tumours. Br J Neurosurg. 1994;8:51–5.CrossRef
23.
Zurück zum Zitat Rix M, et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol. 2004;151:709–15.CrossRef Rix M, et al. Cushing's disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur J Endocrinol. 2004;151:709–15.CrossRef
43.
Zurück zum Zitat Crooke AC, Purves HD, Russell DS, Thornton KR. Hyalinization and basophil adenomata in the pituitary gland. Proc R Soc Med. 1956;49:1014–20.PubMed Crooke AC, Purves HD, Russell DS, Thornton KR. Hyalinization and basophil adenomata in the pituitary gland. Proc R Soc Med. 1956;49:1014–20.PubMed
44.
Zurück zum Zitat George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, et al. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330–6.CrossRef George DH, Scheithauer BW, Kovacs K, Horvath E, Young WF Jr, Lloyd RV, et al. Crooke's cell adenoma of the pituitary: an aggressive variant of corticotroph adenoma. Am J Surg Pathol. 2003;27:1330–6.CrossRef
50.
Zurück zum Zitat Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P. Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol. 2001;12:329–41.CrossRef Holthouse DJ, Robbins PD, Kahler R, Knuckey N, Pullan P. Corticotroph pituitary carcinoma: case report and literature review. Endocr Pathol. 2001;12:329–41.CrossRef
58.
Zurück zum Zitat Oka H, Kameya T, Sasano H, Aiba M, Kovacs K, Horvath E, et al. Pituitary choristoma composed of corticotrophs and adrenocortical cells in the Sella turcica. Virchows Arch. 1996;427:613–7.CrossRef Oka H, Kameya T, Sasano H, Aiba M, Kovacs K, Horvath E, et al. Pituitary choristoma composed of corticotrophs and adrenocortical cells in the Sella turcica. Virchows Arch. 1996;427:613–7.CrossRef
65.
Zurück zum Zitat AbdelBaki MS, Waguespack SG, Salceda V, Jones J, Stapleton SL, Baskin DS, et al. Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. J Neuro-Oncol. 2017;135:213–5. https://doi.org/10.1007/s11060-017-2554-1.CrossRef AbdelBaki MS, Waguespack SG, Salceda V, Jones J, Stapleton SL, Baskin DS, et al. Significant response of pituitary carcinoma to carboplatin, leucovorin and fluorouracil chemotherapy: a pediatric case report and review of the literature. J Neuro-Oncol. 2017;135:213–5. https://​doi.​org/​10.​1007/​s11060-017-2554-1.CrossRef
76.
Zurück zum Zitat Hernández-Ramírez L, C F, Faucz FR, Lodish M, Pankratz N, Chittiboina P, et al. Non-syndromic Cushing's disease due to CDKN1B mutations: novel mutations and phenotypic features in a large pediatric cohort. Journal of the Endocrine Society. 2019;3:OR24–6.CrossRef Hernández-Ramírez L, C F, Faucz FR, Lodish M, Pankratz N, Chittiboina P, et al. Non-syndromic Cushing's disease due to CDKN1B mutations: novel mutations and phenotypic features in a large pediatric cohort. Journal of the Endocrine Society. 2019;3:OR24–6.CrossRef
86.
Zurück zum Zitat Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–83. https://doi.org/10.1210/jc.2009-2556.CrossRefPubMed Daly AF, Tichomirowa MA, Petrossians P, Heliövaara E, Jaffrain-Rea ML, Barlier A, et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab. 2010;95:E373–83. https://​doi.​org/​10.​1210/​jc.​2009-2556.CrossRefPubMed
88.
Zurück zum Zitat Naves LA, Jaffrain-Rea ML, Vêncio SA, Jacomini CZ, Casulari LA, Daly AF, et al. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arq Bras Endocrinol Metabol. 2010;54:761–7.CrossRef Naves LA, Jaffrain-Rea ML, Vêncio SA, Jacomini CZ, Casulari LA, Daly AF, et al. Aggressive prolactinoma in a child related to germline mutation in the ARYL hydrocarbon receptor interacting protein (AIP) gene. Arq Bras Endocrinol Metabol. 2010;54:761–7.CrossRef
113.
Zurück zum Zitat Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol. 1980;35:16–22.CrossRef Kovacs K, Ryan N, Horvath E, Singer W, Ezrin C. Pituitary adenomas in old age. J Gerontol. 1980;35:16–22.CrossRef
116.
Zurück zum Zitat Jaffrain-Rea ML, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103–13.CrossRef Jaffrain-Rea ML, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer. 2002;9:103–13.CrossRef
117.
Zurück zum Zitat Ferrante L, Trillò G, Ramundo E, Celli P, Jaffrain-Rea ML, Salvati M, et al. Surgical treatment of pituitary tumors in the elderly: clinical outcome and long-term follow-up. J Neuro-Oncol. 2002;60:185–91.CrossRef Ferrante L, Trillò G, Ramundo E, Celli P, Jaffrain-Rea ML, Salvati M, et al. Surgical treatment of pituitary tumors in the elderly: clinical outcome and long-term follow-up. J Neuro-Oncol. 2002;60:185–91.CrossRef
118.
Zurück zum Zitat Turner HE, Adams CB, Wass JA. Pituitary tumours in the elderly: a 20 year experience. Eur J Endocrinol. 1999;140:383–9.CrossRef Turner HE, Adams CB, Wass JA. Pituitary tumours in the elderly: a 20 year experience. Eur J Endocrinol. 1999;140:383–9.CrossRef
Metadaten
Titel
Aggressive pituitary tumors in the young and elderly
verfasst von
Christina Tatsi
Constantine A. Stratakis
Publikationsdatum
01.06.2020
Verlag
Springer US
Erschienen in
Reviews in Endocrine and Metabolic Disorders / Ausgabe 2/2020
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-019-09534-8

Weitere Artikel der Ausgabe 2/2020

Reviews in Endocrine and Metabolic Disorders 2/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.